Short Interest in Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) Drops By 9.3%
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 22,400 shares, a decrease of 9.3% from the August 30th total of 24,700 shares. Based on an average daily volume of 6,100 shares, the short-interest ratio is presently 3.7 days. Approximately 1.8% of the company’s shares are short sold.
NASDAQ:SNOA traded up $0.01 on Wednesday, reaching $5.06. 7,441 shares of the company’s stock were exchanged, compared to its average volume of 4,170. The company has a quick ratio of 2.53, a current ratio of 3.35 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $6.12 and a 200-day moving average of $4.16. Sonoma Pharmaceuticals has a 52-week low of $4.85 and a 52-week high of $20.34.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.79) by $2.33. The company had revenue of $4.71 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 39.48% and a negative return on equity of 66.14%.
An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Liberty Wealth Management LLC purchased a new position in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,188 shares of the company’s stock, valued at approximately $33,000. Liberty Wealth Management LLC owned 0.31% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 6.05% of the stock is currently owned by hedge funds and other institutional investors.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.